AtaCor Medical, Inc

AtaCor Medical is pioneering minimally invasive approaches to cardiac procedures through its novel extracardiac pacing and defibrillation technologies. By eliminating the need for intravascular leads and traditional transvenous access, AtaCor is redefining how clinicians manage temporary and permanent cardiac rhythm management.

AtaCor Medical, Inc. is a clinical-stage medical device company dedicated to transforming cardiac rhythm management. The company’s proprietary technology platform enables safe, reliable extracardiac pacing and defibrillation without entering the heart or vasculature.

Founded on the principle that less invasive solutions lead to better patient care, AtaCor is developing groundbreaking devices that reduce procedural complexity, lower complication risks, and expand access to life-saving therapies for patients who need temporary or permanent pacing and defibrillation support.

• Extracardiac Approach — Access the heart from outside the vasculature, eliminating risks associated with transvenous leads such as infection, vascular complications, and lead failure.
• Simplified Procedures — Designed for faster, easier placement with reduced fluoroscopy time and lower procedural risk.
• Improved Patient Safety — Potential to reduce lead-related complications and infections, particularly beneficial for high-risk patients.
• Versatile Applications — Suitable for both temporary pacing/defibrillation and future permanent implant solutions.

• AtaCor’s innovative platform features a unique subcutaneous and extracardiac electrode system that delivers effective pacing and defibrillation therapy while avoiding the traditional challenges of intravascular devices. The technology is being developed for:

  • Temporary post-procedural pacing
  • Bridge-to-permanent device therapy
  • High-risk patients where transvenous access is contraindicated

AtaCor Medical is actively advancing its technology through preclinical and early clinical studies. The company’s first-in-human studies have demonstrated promising safety and performance results, paving the way for larger pivotal trials.

Through its strategic relationship with CorVita, AtaCor Medical benefits from world-class regulatory, clinical, and manufacturing expertise to accelerate development and commercialization of its breakthrough cardiac solutions.